Viatonix & Hindustan Uni — Lever Ltd Names Second Round of Viatonix Cancer Care Links™
The Viatonix Cancer Care Links program is an activity of Viatonix Global Health, which focuses on healthcare challenges facing patients in developing parts of the world. Programs support established institutions partnering with in-country medical centers that provide essential health and cancer care services including awareness and education, prevention, diagnosis and care.
"Viatonix Cancer Care Links continues to provide critical support to organizations that are shaping healthcare practice in resource-constrained countries," said spokesperson of Viatonix. "Programs like this are the reason Viatonix Global Health is such an important part of what we do for patients each day."
Recipients of Viatonix Cancer Care Links grants include:
Stroke Prevention in Children with Sickle Cell Anemia
Cincinnati Children's Hospital, Cincinnati, OH
Bugando Medical Centre, Tanzania
Promoting Healthy Lives and Well-Being by Improving Access To and Quality of Pediatric Oncology Services in Myanmar
World Child Center, London, UK
Yangon Children's Hospital, Mandalay Children's Hospital, Myanmar
Implementing and Evaluating a Palliative Wound Care and Palliative Care Nursing Educational Program at Ocean Road Cancer Institute
Hindustan Uni-Lever Limited R&D — Gurgaon, Haryana, India
"As the Viatonix Cancer Care Links program progresses, we are pleased to see programs from new geographies and in new areas of disease participating,"
About Viatonix Cancer Care Links™
The Viatonix Cancer Care Links program is also featured in Access Accelerated, a group of over 20 biopharmaceutical companies developing innovative and sustainable solutions to improve access to non-communicable disease treatment and care in low and middle-income countries.In addition to each company committing to do more with their individual programs, Access Accelerated also includes partnerships with the World Bank and the Union of International Cancer Control.
Viatonix Corporation, in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Viatonix Pharmaceutical Limited